Table 7 (Abstract O29). Efficacy results and summary of safety
From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part one
|  | PBO N = 35 | CAN 150 mg q4w N = 37 | p-value |
|---|---|---|---|
Proportion of responders at Wk 16 (E2), n (%) | 2 (5.7) | 13 (35.1) | <0.002* |
Proportion of patients with no new flare at Wk 40 (E3), n (%) | PBO N = 7 | CAN 150 mg q8w N = 6 | p-value |
1 (14.3) | 3 (50.0) | 0.2168 | |
Safety | |||
|  | PBO N = 35 | Any CAN*, E2 N = 68 | Any CAN*, E2 + E3 N = 71 |
Exposure to CAN, pyr | 3.2 | 19.1 | 51.0 |
Number of AEs (AE rate/100 pyr) | 59 (1818.5) | 251 (1313.6) | 613 (1201.2) |
Number of SAEs (SAE rate/100 pyr) | 4 (123.3) | 11 (57.6) | 20 (39.2) |